We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Pasithea Therapeutics Corp (KTTA) USD0.0001

Sell:$5.80 Buy:$7.29 Change: $0.14 (2.34%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.14 (2.34%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.14 (2.34%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Contact details

1111 Lincoln Road
United States
+1 (786) 9773380

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$6.28 million
Shares in issue:
1.04 million
United States
US dollar

Key personnel

  • Lawrence Steinman
    Executive Chairman, Co-Founder
  • Tiago Marques
    Chief Executive Officer, Director
  • Daniel Schneiderman
    Chief Financial Officer
  • Graeme Currie
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.